결장직장암과 혈관내피성장인자 발현과의 상관관계 = Expression of Vascular Endothelial Growth Factor in Colorectal Cancer

다국어 초록 (Multilingual Abstract)

Purpose: The neovascularization is an essential factor for
the growth of solid organ cancer and especially vascular
endothelial growth factor (VEGF) has been known to the
very important mediator of neovascularization. Thus, this
study was searching that expression of VEGF in colorectal
cancer correlate to clinicopathologic factors. Methods:
We analyzed 93 patients with sporadic colorectal cancer
who underwent colectomy and their specimens were
studied immunohistochemistry at Chosun University
hospital from March, 2002 to November, 2005. Results:
The expression rate of VEGF was 61 cases of all (65.6%).
There were no significant relation VEGF expression to
age, sex and lymph node metastasis. But, VEGF expression
in colon cancer was 80.5% rather than 53.8% in rectal
cancer (P=0.010). Correlation with T staging, expression
of VEGF was 10.0% in pT0, 62.5% in pT1, pT2 and
77.2% in pT3, pT4 (P＜0.0001), and correlation with
TNM staging, expression of VEGF was 10.0% in stage
0, 63.2% in stage I, 72.0% in stage II, 73.3% in stage
III and 100.0% in stage IV (P=0.001). Conclusions:
Expression of VEGF in colorectal cancer closely correlates
with cancer progression and VEGF was more expressed
in colon cancer than rectum.

다국어 초록 (Multilingual Abstract)

Purpose: The neovascularization is an essential factor for
the growth of solid organ cancer and especially vascular
endothelial growth factor (VEGF) has been known to the
very important mediator of neovascularization. Thus, this
study was searching that expression of VEGF in colorectal
cancer correlate to clinicopathologic factors. Methods:
We analyzed 93 patients with sporadic colorectal cancer
who underwent colectomy and their specimens were
studied immunohistochemistry at Chosun University
hospital from March, 2002 to November, 2005. Results:
The expression rate of VEGF was 61 cases of all (65.6%).
There were no significant relation VEGF expression to
age, sex and lymph node metastasis. But, VEGF expression
in colon cancer was 80.5% rather than 53.8% in rectal
cancer (P=0.010). Correlation with T staging, expression
of VEGF was 10.0% in pT0, 62.5% in pT1, pT2 and
77.2% in pT3, pT4 (P＜0.0001), and correlation with
TNM staging, expression of VEGF was 10.0% in stage
0, 63.2% in stage I, 72.0% in stage II, 73.3% in stage
III and 100.0% in stage IV (P=0.001). Conclusions:
Expression of VEGF in colorectal cancer closely correlates
with cancer progression and VEGF was more expressed
in colon cancer than rectum.

참고문헌 (Reference)

1 Leung DW, "Vascular. endothelial growth factor is a secreted angiogenic mitogen" 246 : 1306-1309, 1989

2 Dvorak HF, "Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy" 20 : 4368-4380, 2002

3 Paley PJ, "Vascular endothelial growth factor expression in early stage ovarian carcinoma" 80 : 98-106, 1997

4 Masood R, "Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors" 98 : 1904-1913, 2001

5 Osella-Abate S, "VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course" 12 : 325-334, 2002

6 Senger DR, "Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid" 219 : 983-985, 1983

7 Folkman J, "Tumor angiogenesis" 43 : 175-203, 1985

8 Houck KA, "The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA" 5 : 1806-1814, 1991

9 Compton CC, "The staging of colorectal cancer: 2004 and beyond" 54 : 295-308, 2004

10 Kim TH, "The significance of the lymphatic micro vessel density and vascular endothelial growth factor- C expression for colorectal cancer" 73 : 406-411, 2007

11 Ferrara N, "The biology of vascular endothelial growth factor" 18 : 4-25, 1997

12 Ferrara N, "The biology of VEGF and its receptors" 9 : 669-676, 2003

13 Hicklin DJ, "Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis" 23 : 1011-1027, 2005

14 Lee JC, "Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients" 36 : 748-753, 2000

15 Griffiths L, "Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy" 76 : 689-693, 1997

16 Jain RK, "Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy" 307 : 58-62, 2005

17 Bergers G, "Modes of resistance to antiangiogenic therapy-targeted therapy" 8 : 592-603, 2008

18 Ministry of Health and Welfare, "Korean Cancer Research 2003" Ministry of Health and Welfare 2003

19 Chen CH, "Fibroblast growth factor 2: from laboratory evidence to clinical application" 2 : 33-43, 2004

20 Schneider BP, "Drug insight: VEGF as a therapeutic target for breast cancer" 4 : 181-189, 2007

21 Mise M, "Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor" 23 : 455-464, 1996

22 August DA, "Clinical perspective of human colorectal cancer metastasis" 3 : 303-324, 1984

23 Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" 350 : 2335-2342, 2004

24 Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" 350 : 2335-2342, 2004

25 Vincenzi B, "Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients" 17 : 835-841, 2006

26 Hertig AT, "Angiogenesis in the early human chorion and in the primary placenta of the Macaque monkey" 25 : 37-81, 1935

27 Giatromanolaki A, "Angiogenesis in colorectal cancer: prognostic and therapeutic implications" 29 : 408-417, 2006

28 Xiangming C, "Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer" 5 : 585-589, 1998

29 Kabbinavar FF, "Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial" 23 : 3697-3705, 2005